Rafael Holdings is no longer a leftover real-estate vehicle with a biotech hobby. After absorbing Cyclo Therapeutics, the Newark holdco is a single-asset rare-disease story waiting on one unblinded Phase Three readout in Niemann-Pick Type C. Last-patient last-visit closed in June. Management has already held a pre-NDA meeting and has stated an NDA filing window in the second half of calendar 2026. That is the entire equity. Everything else on the balance sheet is residual: a Jerusalem office remnant, a majority stub in failed-cancer Cornerstone, LipoMedix, an orthopedic device unit, and Day Three Labs. Howard Jonas sits as chief executive, executive chairman, and chairman of a dual-class controlled company, so the readout is not the only thing that decides residual value. Capital structure and related-party control decide how much of any clinical win actually reaches Class B holders.
The independent data committee reviewed the forty-eight week interim last June and told the company to finish the full study. That is not a win. It is permission to keep spending. Two oral drugs already treat this disease in the United States. Zevra markets MIPLYFFA and IntraBio markets AQNEURSA. Trappsol Cyclo is an intravenous infusion given every other week. If the final data are clean, Rafael still has to sell an infusion against pills. Cash at the April fiscal close was $30.5 million. Nine-month operating cash use ran near $22 million. The Jonas-controlled dual-class structure financed the last raise through a rights offering. Howard Jonas and affiliates backstopped most of that $25 million subscription.
The third-quarter print is not the story. Product sales from early-access cyclodextrin and Jerusalem rent barely register against research spend. The question the next two calendar quarters resolve is whether TransportNPC produces a registrational win large enough to justify an infusion launch into a market that already has two approved orals, and whether the cash box lasts long enough to file without another Jonas-led recap.